Kraig Biocraft Laboratories Inc (KBLB)

[arachnodude]

You say Kim’s credibility issue was self-created. No—it was troll-created, then amplified and recycled by people who refuse to see progress because it doesn’t fit their black-and-white negative worldview.

You claim Kims ‘credibility problem’ is a fact. But a fact is something verifiable, objective, and free from subjective bias. What you’re presenting is an opinion—one based on moving goalposts, selective memory, and a misunderstanding of how innovation in groundbreaking biotech works.

Missed estimates aren't lies, they're adjustments! Spider silk production isn’t a pre-packaged product off a conveyor belt—it’s uncharted territory. Every estimate Kim has given was based on the best information available at the time. When dealing with biological systems, genetic engineering, and environmental variables, timelines shift. That’s not a credibility issue; it’s reality in an industry that’s writing its own rulebook as it goes.

If missing a timeline equals a credibility problem, then every CEO in biotech, aerospace, and advanced manufacturing is guilty. Shall we throw Elon Musk into the 'credibility problem' bucket because Tesla’s production goals didn’t always hit the mark? Of course not, because progress isn’t linear.

You then pivot to the age-old dilution scare tactic. Yes, additional financing may occur—welcome to the reality of every growth-stage biotech company. But dilution isn’t inherently negative. It’s a tool—one that, when used strategically, fuels growth, scales production, and builds long-term shareholder value.

If KBLB takes on funding to bridge a critical stage in production, that’s not ‘harmful dilution.’ That’s responsible capital allocation. Which this CEO has a STRONG history of!

This is where your entire argument collapses under its own weight: If Kim Thompson has such a ‘credibility problem’ and dilution is so certain to crush the share price, why are you still here?

Investing in a company requires belief in the leadership, the technology, and the long-term vision. You can’t simultaneously argue that the CEO can’t be trusted and that you still see value in holding your position. That’s not logical—it’s emotional investing disguised as skepticism.

Kim Thompson isn’t running a lemonade stand—he’s pioneering an entirely new industry. Timelines shift. Estimates adjust. But the one thing that hasn’t changed is the relentless forward progress toward commercial spider silk production.

If you want certainty and predictability, biotech isn’t your game. Go buy an index fund.

But if you’re here, if you’re still holding shares, it means you see the potential—even if you can’t admit it out loud.

So let’s drop the tired ‘credibility issue’ line. It’s not a fact—it’s just your excuse for staying invested while pretending to be above it all.

Time to pick a lane, either you believe in the progress, or you don’t. But stop dressing up your opinion as fact.

#KBLBProgress #FactsOverFUD #TrollLogicFailsAgain"